Zurcher Kantonalbank Zurich Cantonalbank Has $302,000 Stock Holdings in Xencor, Inc. (NASDAQ:XNCR)

Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Xencor, Inc. (NASDAQ:XNCR) by 13.0% during the 4th quarter, HoldingsChannel.com reports. The firm owned 14,215 shares of the biopharmaceutical company’s stock after buying an additional 1,640 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Xencor were worth $302,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Louisiana State Employees Retirement System bought a new position in Xencor in the 4th quarter valued at about $648,000. Mutual of America Capital Management LLC boosted its position in shares of Xencor by 74.4% during the 4th quarter. Mutual of America Capital Management LLC now owns 99,335 shares of the biopharmaceutical company’s stock worth $2,109,000 after acquiring an additional 42,364 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Xencor by 2.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 30,798 shares of the biopharmaceutical company’s stock valued at $654,000 after acquiring an additional 615 shares during the last quarter. Allworth Financial LP increased its stake in shares of Xencor by 29,487.5% in the 4th quarter. Allworth Financial LP now owns 2,367 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 2,359 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Xencor by 354.8% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,041 shares of the biopharmaceutical company’s stock worth $149,000 after buying an additional 5,493 shares in the last quarter.

Wall Street Analyst Weigh In

Several research firms recently weighed in on XNCR. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $32.00 price objective on shares of Xencor in a research note on Wednesday, February 28th. Piper Sandler reaffirmed a “neutral” rating and set a $24.00 price target (down from $37.00) on shares of Xencor in a report on Wednesday, February 28th. BMO Capital Markets dropped their price objective on shares of Xencor from $38.00 to $34.00 and set an “outperform” rating for the company in a research note on Wednesday, February 28th. Mizuho cut their target price on shares of Xencor from $59.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday, January 22nd. Finally, StockNews.com upgraded shares of Xencor from a “sell” rating to a “hold” rating in a report on Saturday, March 9th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $36.00.

Insider Transactions at Xencor

In other news, VP John R. Desjarlais sold 54,108 shares of the stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $19.38, for a total transaction of $1,048,613.04. Following the completion of the sale, the vice president now directly owns 161,675 shares in the company, valued at $3,133,261.50. The transaction was disclosed in a filing with the SEC, which is available at this link. In other news, Director Kurt A. Gustafson sold 14,000 shares of the business’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $23.18, for a total value of $324,520.00. Following the transaction, the director now directly owns 6,007 shares of the company’s stock, valued at approximately $139,242.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP John R. Desjarlais sold 54,108 shares of the firm’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $19.38, for a total value of $1,048,613.04. Following the sale, the vice president now directly owns 161,675 shares of the company’s stock, valued at approximately $3,133,261.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 101,351 shares of company stock worth $2,152,417. Company insiders own 4.97% of the company’s stock.

Xencor Stock Up 2.0 %

Shares of XNCR opened at $24.11 on Monday. The stock’s 50-day moving average price is $21.88 and its two-hundred day moving average price is $20.50. Xencor, Inc. has a 12 month low of $16.49 and a 12 month high of $28.96. The company has a market capitalization of $1.49 billion, a PE ratio of -11.48 and a beta of 0.77. The company has a current ratio of 7.36, a quick ratio of 7.36 and a debt-to-equity ratio of 0.02.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of $0.36 by ($0.67). Xencor had a negative return on equity of 18.67% and a negative net margin of 74.90%. The company had revenue of $44.70 million during the quarter, compared to analyst estimates of $77.63 million. During the same period in the prior year, the firm earned ($0.20) earnings per share. Xencor’s revenue was up 106.9% compared to the same quarter last year. On average, analysts anticipate that Xencor, Inc. will post -3.25 EPS for the current year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.